Postmenopausal Estrogen/Progestin Interventions (PEPI)

Summary

To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Conditions

• Bone Diseases
• Cardiovascular Diseases
• Coronary Disease
• Diabetes Mellitus
• Heart Diseases
• Hypercholesterolemia
• Hypertension
• Myocardial Ischemia
• Osteoporosis
• Thrombosis
• Postmenopause

Interventions

DRUG

estrogens, conjugated

DRUG

medroxyprogesterone

DRUG

progesterone

DRUG

estrogen replacement therapy

Sponsors & Collaborators

• National Institute on Aging (NIA)

  collaborator NIH

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

  collaborator NIH

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  collaborator NIH

• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  collaborator NIH

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• Mark Espeland · Bowman Gray School of Medicine

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Eligibility

Min Age

45 Years

Max Age

64 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

1987-09-30

Completion

2000-10-31